Leerink Partners on Arrowhead Pharma (ARWR): SRPT data drives shares up despite IONS pricing update

March 25, 2026 3:05 PM

Leerink Partners analyst Mani Foroohar reiterated a Market Perform rating and $61.00 price target on Arrowhead Pharma (NASDAQ: ARWR)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found